×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GSK – gsk plc american depositary shares (each representing two ordinary shares) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GSK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
02:03 am
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
12/12
02:03 am
gsk
GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
12/9
01:38 pm
gsk
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
Low
Report
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
12/4
11:21 pm
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/15
08:17 am
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.
11/12
08:03 am
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $39.50 price target on the stock, down previously from $53.00.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $39.50 price target on the stock, down previously from $53.00.
10/31
07:10 am
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
10/26
09:32 am
gsk
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' [Seeking Alpha]
Low
Report
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
8 Best Pharmaceutical Stocks to Buy for Income [Yahoo! Finance News]
6.6%
3/3 GlaxoSmithKline Reportedly Trying Again to Sell Antibiotics Line [The Motley Fool] 5.1%
3/2 Form 6-K GLAXOSMITHKLINE PLC For: Mar 02 4.9%
4/16 UPDATE 2-'Too early' to lift UK lockdown but coronavirus outbreak peaking, minister says [Reuters] 3.7%
3/24 Form 6-K GLAXOSMITHKLINE PLC For: Mar 24 3.7%
7/24 REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix [Reuters] 2.5%
5/21 What Older Adults Need To Know About Measles And Shingles Vaccines [Forbes] 2.3%
7/19 Inside The Pharmaceutical Lobby's Campaign For More Government Subsidies Through Medicare Part D [Forbes] 2.2%
4/8 Gilead: Upside From Potential Coronavirus Treatment Could Dissipate [Seeking Alpha] 2.1%
6/6 Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options 2.1%
3/3 GlaxoSmithKline Reportedly Trying Again to Sell Antibiotics Line [The Motley Fool] 5.1%
3/2 Form 6-K GLAXOSMITHKLINE PLC For: Mar 02 4.9%
4/16 UPDATE 2-'Too early' to lift UK lockdown but coronavirus outbreak peaking, minister says [Reuters] 3.7%
3/24 Form 6-K GLAXOSMITHKLINE PLC For: Mar 24 3.7%
7/24 REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix [Reuters] 2.5%
5/21 What Older Adults Need To Know About Measles And Shingles Vaccines [Forbes] 2.3%
7/19 Inside The Pharmaceutical Lobby's Campaign For More Government Subsidies Through Medicare Part D [Forbes] 2.2%
4/8 Gilead: Upside From Potential Coronavirus Treatment Could Dissipate [Seeking Alpha] 2.1%
6/6 Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options 2.1%
TOP News Decliners
3/20
Form 6-K GLAXOSMITHKLINE PLC For: Mar 20
-3.9%
3/6 Form 20-F GLAXOSMITHKLINE PLC For: Dec 31 -3.9%
3/2 Here's Why Shares of AnaptysBio Jumped Today [The Motley Fool] -3.8%
4/15 UPDATE 1-The world will need more than one COVID-19 vaccine, GSK CEO says [Reuters] -3.2%
2/23 Better Buy: GlaxoSmithKline vs. Eli Lilly [The Motley Fool] -2.9%
10/1 GlaxoSmithKline (GSK) Presents At ESMO Congress 2019 - Slideshow [Seeking Alpha] -2.6%
2/5 GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -2.6%
4/28 Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline [The Motley Fool] -2.5%
5/13 Form 6-K GLAXOSMITHKLINE PLC For: May 13 -2.4%
5/7 UPDATE 1-UK Stocks-Factors to watch on May 7 [Reuters] -2.3%
3/6 Form 20-F GLAXOSMITHKLINE PLC For: Dec 31 -3.9%
3/2 Here's Why Shares of AnaptysBio Jumped Today [The Motley Fool] -3.8%
4/15 UPDATE 1-The world will need more than one COVID-19 vaccine, GSK CEO says [Reuters] -3.2%
2/23 Better Buy: GlaxoSmithKline vs. Eli Lilly [The Motley Fool] -2.9%
10/1 GlaxoSmithKline (GSK) Presents At ESMO Congress 2019 - Slideshow [Seeking Alpha] -2.6%
2/5 GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -2.6%
4/28 Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline [The Motley Fool] -2.5%
5/13 Form 6-K GLAXOSMITHKLINE PLC For: May 13 -2.4%
5/7 UPDATE 1-UK Stocks-Factors to watch on May 7 [Reuters] -2.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: